Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma.
- Author:
Xin LI
1
;
Yu-Ping ZHONG
;
Ying HU
;
Jia-Jia ZHANG
;
Na AN
;
Shi-Lun CHEN
Author Information
1. Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Boronic Acids;
administration & dosage;
Bortezomib;
Female;
Humans;
Male;
Methylprednisolone;
administration & dosage;
Middle Aged;
Multiple Myeloma;
drug therapy;
pathology;
Neoplasm Recurrence, Local;
drug therapy;
Pyrazines;
administration & dosage;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2011;19(4):987-990
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to explore the clinical effect and toxicity of bortezomib combined with methylprednisolone in treatment of relapsed or refractory multiple myeloma (MM). Clinical data of 33 patients (23 male, 10 female; aged from 38 to 85 years old) were analyzed retrospectively. The median diagnosis time was 25 (2 - 120) months. 33 patients received bortezomib (0.9 - 1.1) mg/m(2) on days 1, 4, 8, 11, in combination with methylprednisolone 40 mg/d (4 cases), 80mg/d (13 cases), 120 mg/d (2 cases), 200 mg/d (9 cases), 300 mg/d (5 cases) respectively. The median follow-up time was 10(3-60) months. The used therapy courses were 1 - 8 (mean 4 courses). The results indicated that 24 cases showed the response of different degree, the overall response rate (ORR) was 72.7% (24/33). 32 patients received ≥ 2 therapy courses, and ORR was 71.9% (23/32). 16 patients received 4 therapy courses, and ORR was 93.8% (15/16 cases). 7 patients received 6 therapy courses and the ORR was 100% (7/7 cases). Main side-effects were thrombocytopenia, infection and peripheral neuropathy. The median survival time was 41.5 (2 - 120) months and the 2-year, 3-year and 5-year overall survival rate were 80%, 59.1% and 21.1%, respectively. It is concluded that bortezomib combined with methylprednisolone is an effective therapy with higher response rate, and safe in treatment of relapsed or refractory multiple myeloma.
